Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing
- 1 June 2019
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 81 (2) , 158-162
Abstract
Background: Objective adherence metrics for tenofovir (TFV) disoproxil fumarate/emtricitabine (FTC)-based pre-exposure prophylaxis (PrEP) were critical for interpretation of efficacy in PrEP clinical trials, and there is increasing interest in using drug levels to tailor interventions for reengagement and adherence. Point-of-care immunoassays for TFV, which examine short-term adherence, are in development. However, the ability of poor short-term and long-term adherence to predict future PrEP nonretention is unknown. Setting: Secondary data analysis of a large, prospective multi-site U.S. PrEP demonstration project. Methods: An adjusted Cox-proportional hazards model examined the relationship of dried blood spot (DBS) levels of FTC-triphosphate (FTC-TP) or TFV-diphosphate (TFV-DP), measures of short-term and long-term PrEP adherence, respectively, with future study nonretention. Results: Overall, 294 individuals (median age 33 years) contributed drug levels within the U.S. PrEP demonstration project. By the end of study, 27% were lost to follow-up, 25% had at least one undetectable FTC-TP level indicating poor short-term adherence, and 29% had a drug level indicating suboptimal long-term adherence (TFV-DP <700 fmol/punch). The strongest factor associated with future study nonretention using a binary drug-level cut-off was an undetectable DBS FTC-TP level (adjusted hazard ratio 6.3; 95% confidence interval 3.8 to 10.2). The suboptimal long-term adherence based on low DBS TFV-DP levels was also associated with nonretention (adjusted hazard ratio 4.3; 95% confidence interval: 2.4 to 7.6). Conclusions: Both short- and long-term metrics of PrEP adherence are strongly associated with future loss to follow-up in a U.S. demonstration project study. Short-term metrics of adherence, once available at the point-of-care, could be used to direct real-time tailored retention and adherence interventions.Keywords
This publication has 25 references indexed in Scilit:
- Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United StatesJAMA Pediatrics, 2017
- Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
- Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre‐exposure prophylaxisHIV Medicine, 2017
- An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSMJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
- Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinicAIDS Care, 2016
- Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical SettingPLOS ONE, 2016
- Retention in care outcomes for HIV pre‐exposure prophylaxis implementation programmes among men who have sex with men in three US citiesJournal of the International AIDS Society, 2016
- Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health ServicesJAMA Internal Medicine, 2016
- Antiretroviral Refill Adherence Correlates with, But Poorly Predicts Retention in HIV CareAIDS and Behavior, 2015
- Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyThe Lancet Infectious Diseases, 2014